Following further analysis, five DEGs (SELE, TREM1, AQP9, FPR2, and HCAR3) were significantly upregulated in the IBD patients who do not respond to infliximab treatment, serving as potential biomarkers for infliximab resistance. Here, AQP9 is linked to inflammatory bowel disease.